Anti-Dabigatran Recombinant Antibody (Idarucizumab) (CAT#: TAB-H40)

Recombinant Humanized antibody to dabigatran


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Datasheet
  • MSDS
  • COA

Figure 1 Pharmacokinetic data.

Figure 1 Pharmacokinetic data.

Geometric mean idarucizumab plasma concentration-time profiles from the start of a single infusion of 1 g to 4 g idarucizumab for 5 minutes on (A) a linear scale and (B) a semi-log scale.

Reilly, P. A., van Ryn, J., Grottke, O., Glund, S., & Stangier, J. (2016). Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects. The American journal of medicine, 129(11), S64-S72.

Figure 2 Effect of idarucizumab or placebo infusion on coagulation variables, (A) dTT, (B) ECT, (C) aPTT and (D) TT.

Figure 2 Effect of idarucizumab or placebo infusion on coagulation variables, (A) dTT, (B) ECT, (C) aPTT and (D) TT.

Dotted horizontal lines show upper limit of normal. "0 h" and the arrows on x axes show when the idarucizumab or placebo infusion ended. Solid horizontal lines show the mean baseline measurement. Data points show mean; error bars show standard error. aPTT = activated partial thromboplastin time; DE = dabigatran etexilate; dTT = diluted thrombin time; ECT = ecarin clotting time.

Reilly, P. A., van Ryn, J., Grottke, O., Glund, S., & Stangier, J. (2016). Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects. The American journal of medicine, 129(11), S64-S72.


Specifications

  • Host Species
  • undefined
  • Derivation
  • Humanized
  • Type
  • Fab - G1 - kappa
  • Specificity
  • dabigatran etexilate mesylate (Pradaxa®)
  • Species Reactivity
  • N/A
  • Applications
  • IP, IF, FuncS, FC, Neut, ELISA, IHC, PK, Activ
  • CAS
  • 1362509-93-0
  • Generic Name
  • idarucizumab
  • MW
  • 47.8 kDa
  • Related Disease
  • Overdose of dabigratran etexilate mesylate (Pradaxa®)(an oral anticoagulant, direct thrombin inhibitor)

Product Property

  • Purity
  • >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Applications

  • Application Notes
  • The dabigatran antibody has been reported in applications of IP, IF, FuncS, FC, Neut, ELISA, IHC, PK, Activ.

Target

  • Alternative Names
  • idarucizumab;1362509-93-0;dabigatran;Pradaxa;Pradax;Prazaxa

Related Resources

  • Biosimilar Overview
Please refer to Idarucizumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Idarucizumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "dabigatran"

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-H40. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare